

Nivolumab CheckMate-816

### PRELIMINARY SCORE

**CURATIVE**



**NON-CURATIVE**



### ADJUSTMENTS

**Quality of life**



Not qualified for an ESMO-MCBS credit



**Serious and disabling adverse effects**



**Other adjustments**



Nivolumab CheckMate-816

### SCORE

**CURATIVE**



Overall Survival / Disease-Free Survival / Pathological Complete Response

**NON-CURATIVE**



Overall Survival




Progression-Free Survival



Non-inferiority (Improved Quality of Life or Reduced Adverse Events) / Response Rate



Overall Response Rate / Duration of Response



Overall Survival / Disease-Free Survival / Pathological Complete Response

**INFORMATION**

Tumour type: Thoracic Malignancies

Therapeutic Indication: Treatment of adult patients with resectable non-small cell lung cancer in the neoadjuvant setting

Experimental Arm: Nivolumab + Platinum-doublet ChT

Control Arm: Platinum-doublet ChT

